D. Custeau

Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.

David A. Scott, P. Lyne, L. Drew, 2009, Bioorganic & medicinal chemistry letters.

Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents.

H. Gourdeau, S. Kasibhatla, L. Geerts, 2004, Molecular cancer therapeutics.

Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity

H. Gourdeau, T. Bowlin, D. Custeau, 2001, Cancer Chemotherapy and Pharmacology.

Discovery of 1-((6-Aminopyridin-3-yl)Methyl)-3-(4-Bromophenyl)Urea as a Potent, Irreversible Myeloperoxidase Inhibitor

L. Hamann, J. Marcinkeviciene, Lihe Zhang, 2018, The Journal of Pharmacology and Experimental Therapeutics.

The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domain.

T. Chittenden, H. Gourdeau, C. Vater, 2001, Molecular cancer therapeutics.

Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics

H. Gourdeau, J. Jolivet, L. Leblond, 2004, Clinical Cancer Research.